Precision Treatment Options for Primary and Metastasized Bone Cancers
Envita Medical Centers’ uniquely integrative
personalized approach to late-stage bone cancer utilizes next-level precision care including extensive genomic
targeting, advanced immunotherapy, modulation of tumor microenvironment and specialized precision non-invasive surgery
directed at the periosteum of the bone tumor and other satellite regions where the tumors reside. This
all-encompassing approach helps our patients improve their overall responses to treatment.
Envita Medical Centers doesn't make any guarantee of outcomes. Results are not typical and will vary
person to person and should not be expected.
EnvitaIR™: A Non-Invasive Surgical Option for Bone Cancer Patients
Interventional Radiology (IR) is one of the many treatment options available for patients seeking bone cancer care.
IR utilizes medical imaging and minimally invasive surgical procedures for oncological treatment of difficult to reach
cancer types like cancers of the bone. With over 20 years of developing precision medicine and expanding non-invasive
surgical options for late-stage and complex cancer patients, Envita Medical Centers has created EnvitaIR™, Envita’s
Interventional Radiology and Immunotherapy Center.
EnvitaIR™ takes interventional radiology to the next level by incorporating patient-specific treatment algorithms
based on exhaustive laboratory testing which targets proprietary customized immunotherapy and immunotherapy adjunctive
agents best suited for the patient’s state of disease. Precision drug delivery via micro catheters allows for targeted
deployment of conventional and custom compounded, patient-specific medication for localized and systemic effect
throughout the patient’s body.
EnvitaIR™ takes full advantage of the latest advancements in precision interventional oncology using chemotherapy,
radiation, and ablation therapy for direct tumor kill. Even further, EnvitaIR™ harnesses minimally invasive procedures
to deliver genetically targeted immunotherapies, customized for each patient’s form of cancer, to regulate
immunoreactive blockades that compromise the immune system.
Advantages of Envita Interventional Radiology
EnvitaIR's™ procedures are performed without the need for large surgical incisions. Treatment is performed
using small catheters the size of a human hair that are fed through the patient's veins to the area of
interest allowing for precision administration with significantly faster recovery.
Because EnvitaIR's™ treatments are minimally invasive, there is no need for general anesthesia reducing the
health risks that can result from being put into a medically induced coma to perform a procedure.
EnvitaIR's™ has developed genetically targeted interventional radiology procedures that deliver
patient-specific genomic agents directly to the tumor.
Tumor targeted genomic agent delivery causes a systemic immune system response that activates the immune
system to seek out other metastatic cancer sites in the body.
Generally, the recovery time from a procedure will be much faster than traditional surgery methods due to its
minimally invasive administration.
EnvitaIR's™ procedures are performed in an outpatient setting by dedicated and highly trained medical
professionals where an overnight hospital stay is not necessary.
There are many benefits to EnvitaIR’s™procedures but the truly unique factor is the precision custom genomic
and immunotherapy options that are directly administered at the tumor site. This technology takes
interventional oncology to the next level.
The key to Envita’s world-class, revolutionary care is
tumor-specific, precision genomic analysis of real-time mutational rates and immune targets, combined with Envita’s
proprietary treatment algorithms developed over our extensive years of experience working with late-stage and complex
cancers. Envita’s highly experienced physicians use this critical information to formulate a customized treatment plan
based on you, the patient, and your unique bone cancer expression.
Envita Medical Centers is at the forefront of medical technology, combining leading-edge precision cancer treatments
with the latest innovations in non-invasive surgery, efficacious traditional medicine, and custom compounded natural,
IV-based agents. For twenty years, Envita has helped thousands of late-stage and resistant-to-care cancer patients
find amazing results through personalized protocols that are genetically optimized to treat each patient’s unique
cancer, including primary sarcomas and metastatic bone tumors.
Let Envita Medical Centers be your Center of Excellence in the practice of precision integrative medicine for
late-stage and refractory-to-care bone cancer. Through our two decades of clinical experience, Envita recognizes bone
cancer patients need a precision-based approach utilizing advanced personalized treatment options that have been
genetically targeted towards the patient’s specific actionable targets that are driving metastatic cancers.
The ability to provide this level of detailed analysis is why Envita stands out among other big-name facilities.
Envita Medical Centers designs personalized protocols for
late-stage cancer patients that have failed previously recommended treatments, going above-and-beyond the
standardized approach to care.
Advanced Genetic Testing
Accurately targeting bone cancer is critically important. Late-stage
metastasized cancers like cancers of the bone pose significant challenges to standard-of-care treatment regimens
because often these cancers were not responsive to first and second-round treatment options, causing the cancer to
grow uncontrollably. Moreover, the wrong chemotherapy selection can accelerate mutational rates and worsen a patient’s
Standard of care’s one-size-fits-all, blanket treatments have little flexibility within their protocols to deal with
these rapidly changing expressions of cancer. This approach to cancer treatment is best described as trying to hit a
moving target by only focusing on where the target is at, as opposed to where it is going.
To understand the cancers trajectory and how to properly target it, next-generation genetic testing becomes the
essential first step towards targeted treatment. With twenty years of clinical experience treating metastatic cancers,
Envita physicians have found that having accurate real-time data is critical to discovering actionable targets for
precision care. Using precision analysis of advanced genetic data and the patient’s complete medical history, Envita
builds completely customized genetically targeted protocols for each patients’ unique needs, providing a higher degree
of personalized medicine.
Envita’s precision analysis of the most up-to-date genomics is used to identify targets for care which include the
cancer’s microenvironment, microsatellite instability, epigenetic influences on mutation, and suppressed
immuno-reactivity. It is only when all these areas have been properly tested for and addressed can a patient begin to
experience true personalized care.
Standard cancer care does not adequately address the continuously updating genetic information on cancer biomarkers
and chemo susceptibility, which are important for staying ahead of the constantly changing cancer environment. Advanced immunotherapy and
immunotherapy adjunctive agents are essential in activating the body’s immune system to reestablish its ability
to fight cancerous lesions.
By utilizing precision-based genetic testing to determine patient-specific oncogenes and tumor suppressor genes
correlated with a patient’s unique cancer presentation, Envita can put the pieces together and create a personalized
medical blueprint designed to attack the cancer from multiple angles with dynamic protocols that update with the
Envita Medical Centers doesn't make any guarantee of outcomes. Results are not typical and will vary
person to person and should not be expected.
This real-time information guides advancements in Envita’s personalized epigenomic and miRNA protocols designed to
downregulate oncogenes and upregulate tumor suppressor genes. Oncogenes are responsible for perpetuating the growth
and spread of cancer, while tumor suppressor genes are genes that can reactivate the body's immune response against
A healthy immune system can precisely and efficiently kill thousands of cancerous cells daily. Envita’s unique
treatment options work to correct and take advantage of these processes by identifying and modulating patient-specific
oncogenes and tumor suppressor genes to turn off cancer signaling and turn on the immune system’s ability to identify
and attack the cancerous cells.
Finally, treating the causes of cancer can be just as important as attacking cancerous cells themselves. Envita
utilizes extensive genomic testing to identify toxins, infections, and other harmful agents that may be playing a role
in not only proliferating cancerous cell growth and formation but also limiting treatment efficacy and suppressing the
patient’s immune system.
A comprehensive treatment protocol that is personalized to match each patients’ individual needs and their cancers
unique weaknesses is key in creating Envita’s customized treatment plans. The medical blueprint Envita develops based
on state-of-the-art testing is a cornerstone for providing this high level of precision treatment.
Treating Metastasized Cancers
Envita’s advanced genetic analysis provides crucial information about a patient’s cancer, its mutations, and the
microenvironment surrounding the tumor. Cancer’s microenvironment
contains many crucial elements that need to be addressed in order to successfully eradicate the tumor and halt
metastasis. These elements include Circulating Tumor Cells (CTCs), Vascular Endothelial Growth Factors (VEGF), and
Microsatellite Instability (MSI).
Evidence suggests that Circulating Tumor Cells or CTCs carry the most recently mutated form of the cancer’s genetic
markers . Envita employs proprietary technology designed to corral these CTC’s and provide real-time genetic
information which is used to detail the patient’s medical blueprint and their metastasized cancer’s genetic
A patient’s medical blueprint is used in combination with Envita’s customized treatment algorithms to precisely track
and treat mutational rates, immunotherapy targets, and genomic markers. Using this blueprint and twenty years of
clinical experience treating metastatic cancers, Envita doctors create a detailed and customized
comprehensive treatment strategy that focuses on addressing key factors in the development and circulation of
Vascular Endothelial Growth Factors, or VEGFs, promote the formation of new and irregular blood vessels . These
irregular vessels can help tumors grow, and cancerous cells spread . Envita’s doctors utilize personalized
treatment protocols that combine customized integrative medicines with antiangiogenic smart drug technology that can
silence cancerous blood vessel growth.
By tracking and treating the unique microenvironment around the cancer, Envita’s personalized treatment protocols are
designed to potentially decelerate and prevent further metastasis by slowing the spread of CTCs.
Microsatellite Instabilities (MSI) are theorized to be the outcome of mutations that occur during DNA replication
. MSI can facilitate the continued mutation of the cancerous cells in the bone and throughout the body ,
resulting in constantly changing treatment targets that can complicate and derail treatments.
Envita utilizes next generation testing to accurately measure mutational rates and develop precision treatment
algorithms to deploy correlated therapies. Envita has developed treatments to address microsatellite instability to
help keep our patients one step ahead of their disease and improve their chances for a positive outcome.
Precision interventional oncology solutions provide treatment options that not only target the cancerous regions
directly, but also incorporate epigenomic and miRNA immunotherapy designed to address the microenvironment supporting
the growth and mutation of the cancer. These treatments offer options far beyond what may be available from
conventional radiology and invasive surgery for bone cancers.
CIPI™, one of Envita’s most exciting new interventional radiology treatment options, utilizes the precision
techniques of interventional non-invasive surgery with micro-dosed chemotherapy delivered directly to the tumor,
offering a unique approach to treatment of complex cancers.
CIPI™: Chemo Immuno Precision Injections
For many late-stage and progressive cancer patients, continuing to perform untargeted chemotherapy regimens can lead
to further cancerous mutations. This is especially common for patients with tumors that are difficult to penetrate and
reach through traditional chemotherapy administration options, like bone cancers.
Envita Medical Centers is one of the world’s leading integrative medical centers focused on innovating and improving
technologies and therapies to better serve the needs of cancer patients. For patients suffering from bone cancers and
other hard to treat tumors, Envita is excited to offer a customized precision approach to interventional oncology
Immuno Precision Injections
The CIPI™ procedures ingenuity lies in its personalized interventional radiology approach that precisely delivers
genetically targeted medications directly into the cancerous tumors, while leaving the patient with potentially
reduced side-effects from the use of minimally invasive delivery techniques.
By utilizing the patient’s advanced medical blueprint and delivering truly personalized care, Envita provides a level
of precision medicine that goes beyond what other treatment centers can offer. The proprietary therapies derived
combines comprehensive and highly detailed testing with genetically targeted medications and natural adjuvant agents,
allowing for customized treatments that focus on the patient’s specific needs.
Immuno-Ablation is another innovative and leading-edge therapy that allows Envita’s physicians to deliver precision
ablation to painful spinal and bone tumors after establishing immunoreactivities to the cancer. The treatment aims to
stimulate immunity via periosteum activation at the bone cancer site.
The bone is a hematopoietic organ that is involved in the origination of red blood cell and immune cells. These
mutated cells add complexity to mutation along with immune system resistance to treatment.
Immuno-ablation focuses on reestablishing the body’s immunity to the cancer and then ablating the tumor using a
minimally invasive approach that allows for faster recovery. This alternative to highly invasive surgery can also
destroy painful metastatic tumors in a simple outpatient procedure that has a minimal potential for side-effects.
Envita’ s interventional radiology division provides the ability to directly target bone tumors without the need to
put the patient under general anesthesia to perform extremely invasive surgical procedures, which have their own risks
beyond the tumor itself, greatly improving the quality of life and recovery for the patient.
Envita Medical Centers has spent twenty years treating the most aggressive and resistant late-stage cancers. In that
time, we have helped thousands of cancer patients from all around the world, including many stage four cancers
patients with metastatic bone cancer, find real success against their condition.
We know that most cases of bone cancer result from late-stage cancers that have spread throughout the body, and this
can result in resistant cancers that can be difficult to treat. The standard protocols for treating these late-stages
of cancer and metastasized bone cancers may involve invasive surgeries and one-size-fits-all chemotherapies or
These methods can cause extensive damage when not properly targeted, therefore Envita strives to offer the most
advanced personalized therapies and treatment protocols from around the world to help patients that are looking for
By utilizing in-depth genetic testing combined with one-of-a-kind targeted treatments, Envita stacks the odds in the
patients favor to potentially achieve positive outcomes. Many patients finish treatment at Envita and wish they would
have found us sooner; they leave grateful to have experienced the incredible healing that happens at Envita Medical
Our team of 160 dedicated staff from physicians, chemists, pharmacists, and researchers working with the most
difficult and late-stage cancers recognize that the sooner detailed planning and precision is implemented for your
care, the better your chances for success in our clinical experience.
To learn more about how we may be able to help you with your specific situation contact us; we have expert team that
works hand and hand with our doctors to help review your case and we are here to help.
If you or a loved one is suffering from metastatic bone cancer, please do not hesitate to reach out to Envita’s
Patient Care Team at 866-830-4576 and let us help you discover the power of targeted and personalized care.
 Van der Toom, E.E., et al., Technical challenges in the isolation and analysis of circulating tumor cells.
Oncotarget, 2016. 7(38): p. 62754-62766.
 Kowanetz, M. and N. Ferrara, Vascular Endothelial Growth Factor Signaling Pathways: Therapeutic Perspective.
Clinical Cancer Research, 2006. 12(17): p. 5018.
 Boland, C.R. and A. Goel, Microsatellite Instability in Colorectal Cancer. Gastroenterology, 2010. 138(6): p.
 Park, S.W., et al., Somatic frameshift mutations of bone morphogenic protein receptor 2 gene in gastric and
colorectal cancers with microsatellite instability. APMIS, 2010. 118(11): p. 824-829.